相似文献
1
Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.
J Clin Microbiol. 2016 Apr;54(4):840-4. doi: 10.1128/JCM.02424-15. Epub 2016 Jan 20.
2
Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.
J Infect Dev Ctries. 2014 Mar 13;8(3):289-96. doi: 10.3855/jidc.3335.
3
Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations.
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:166-8. doi: 10.1111/j.1469-0691.2007.01859.x.
4
Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:169-74. doi: 10.1111/j.1469-0691.2007.01856.x.
5
Prevalence of beta-lactam nonsusceptible Gram-negative bacilli and use and interpretation of current susceptibility breakpoints: a survey of infectious disease physicians.
Diagn Microbiol Infect Dis. 2011 Nov;71(3):316-9. doi: 10.1016/j.diagmicrobio.2011.07.013. Epub 2011 Sep 6.
6
Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
Diagn Microbiol Infect Dis. 2005 Jul;52(3):235-46. doi: 10.1016/j.diagmicrobio.2005.02.006.
7
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
J Antimicrob Chemother. 2012 Jan;67(1):159-66. doi: 10.1093/jac/dkr400. Epub 2011 Oct 3.
8
Antimicrobial stewardship of β-lactams in intensive care units.
Expert Rev Anti Infect Ther. 2014 May;12(5):581-95. doi: 10.1586/14787210.2014.902308. Epub 2014 Mar 22.
9
Analysis of Potential β-Lactam Surrogates To Predict Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae.
J Clin Microbiol. 2018 Mar 26;56(4). doi: 10.1128/JCM.01892-17. Print 2018 Apr.
10
Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?
Enferm Infecc Microbiol Clin. 2014 Dec;32 Suppl 4:33-40. doi: 10.1016/S0213-005X(14)70172-7.
引用本文的文献
1
Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI).
Antimicrob Steward Healthc Epidemiol. 2022 Mar 11;2(1):e39. doi: 10.1017/ash.2022.21. eCollection 2022.
2
Genomic surveillance for multidrug-resistant or hypervirulent Klebsiella pneumoniae among United States bloodstream isolates.
BMC Infect Dis. 2022 Jul 7;22(1):603. doi: 10.1186/s12879-022-07558-1.
3
The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities.
Front Pharmacol. 2022 Apr 25;13:841896. doi: 10.3389/fphar.2022.841896. eCollection 2022.
4
Effect on Antimicrobial Resistance of a Policy Restricting Over-the-Counter Antimicrobial Sales in a Large Metropolitan Area, São Paulo, Brazil.
Emerg Infect Dis. 2022 Jan;28(1):180-187. doi: 10.3201/eid2801.201928.
5
Genomic diversity of antimicrobial resistance in non-typhoidal in Victoria, Australia.
Microb Genom. 2021 Dec;7(12). doi: 10.1099/mgen.0.000725.
6
Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with , , or : The Importance of the CLSI Breakpoints Revision.
Infect Drug Resist. 2021 Aug 31;14:3541-3552. doi: 10.2147/IDR.S329477. eCollection 2021.
7
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0120421. doi: 10.1128/AAC.01204-21. Epub 2021 Aug 16.
8
Reporting antimicrobial susceptibilities and resistance phenotypes in Staphylococcus spp.: a nationwide proficiency study.
J Antimicrob Chemother. 2021 Apr 13;76(5):1187-1196. doi: 10.1093/jac/dkab017.
9
Amino Acid -mer Feature Extraction for Quantitative Antimicrobial Resistance (AMR) Prediction by Machine Learning and Model Interpretation for Biological Insights.
Biology (Basel). 2020 Oct 28;9(11):365. doi: 10.3390/biology9110365.
10
Minimizing Time to Optimal Antimicrobial Therapy for Enterobacteriaceae Bloodstream Infections: A Retrospective, Hypothetical Application of Predictive Scoring Tools vs Rapid Diagnostics Tests.
Open Forum Infect Dis. 2020 Jul 2;7(8):ofaa278. doi: 10.1093/ofid/ofaa278. eCollection 2020 Aug.
本文引用的文献
1
Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC.
Diagn Microbiol Infect Dis. 2015 Jun;82(2):165-71. doi: 10.1016/j.diagmicrobio.2015.03.005. Epub 2015 Mar 10.
2
Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints.
J Clin Microbiol. 2014 Jul;52(7):2653-5. doi: 10.1128/JCM.03613-13. Epub 2014 Apr 30.
3
Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.
Int J Antimicrob Agents. 2014 May;43(5):456-9. doi: 10.1016/j.ijantimicag.2014.01.030. Epub 2014 Mar 18.
4
Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.
J Infect Dev Ctries. 2014 Mar 13;8(3):289-96. doi: 10.3855/jidc.3335.
5
Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
J Antimicrob Chemother. 2014 Apr;69(4):871-80. doi: 10.1093/jac/dkt450. Epub 2013 Nov 20.
6
Medical students' perceptions and knowledge about antimicrobial stewardship: how are we educating our future prescribers?
Clin Infect Dis. 2013 Sep;57(5):631-8. doi: 10.1093/cid/cit370. Epub 2013 May 31.
7
Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
Int J Antimicrob Agents. 2013 Apr;41(4):383-7. doi: 10.1016/j.ijantimicag.2012.12.003. Epub 2013 Feb 1.
8
Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
Clin Infect Dis. 2013 May;56(9):1301-9. doi: 10.1093/cid/cit017. Epub 2013 Jan 18.
9
Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
Clin Infect Dis. 2013 Feb;56(4):488-95. doi: 10.1093/cid/cis916. Epub 2012 Oct 22.
10
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.
J Antimicrob Chemother. 2012 Dec;67(12):2793-803. doi: 10.1093/jac/dks301. Epub 2012 Aug 21.
Zotero 插件